Supply chain security and transparency is a key part of the risk mitigation strategy of companies manufacturing clinical diagnostic assays. Prior to the COVID-19 crisis, complex global supply chains carefully balanced capacity with demand while cost-cutting initiatives pushed towards lower cost raw material providers located in different geographies. COVID-19-driven regional manufacturing shutdowns, surge demands and logistics disruptions have placed significant pressure on clinical diagnostic supply chains, resulting in raw material shortages and delays.
Download this whitepaper to learn more about key considerations when selecting a contract manufacturing partner such as:
- Do they produce their own raw materials?
- What are the costs of their raw materials?
- • Have they secured a secondary source of critical raw components?